Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)

Migration, Crosslink

📖

Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-alpha-synuclein-seeding-

📖 Wiki Page

biomarker3012 wordssynced 2026-04-02

Overview

flowchart TD biomarkers_alpha_synuclein_see["Alpha-Synuclein Seeding Assays RT-QuIC and PMCA"] biomarkers_alpha_synuclein_see["Alpha-synuclein"] biomarkers_alpha_synuclein_see -->|"related to"| biomarkers_alpha_synuclein_see style biomarkers_alpha_synuclein_see fill:#81c784,stroke:#333,color:#000 biomarkers_alpha_synuclein_see["assays"] biomarkers_alpha_synuclein_see -->|"related to"| biomarkers_alpha_synuclein_see style biomarkers_alpha_synuclein_see fill:#81c784,stroke:#333,color:#000 biomarkers_alpha_synuclein_see["ultrasensitive"] biomarkers_alpha_synuclein_see -->|"related to"| biomarkers_alpha_synuclein_see style biomarkers_alpha_synuclein_see fill:#81c784,stroke:#333,color:#000 biomarkers_alpha_synuclein_see["biochemical"] biomarkers_alpha_synuclein_see -->|"related to"| biomarkers_alpha_synuclein_see style biomarkers_alpha_synuclein_see fill:#81c784,stroke:#333,color:#000 style biomarkers_alpha_synuclein_see fill:#4fc3f7,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Alpha-synuclein seeding assays are ultrasensitive biochemical tests that detect the pathological seeding capability of misfolded [alpha-synuclein](/proteins/alpha-synuclein) protein in biological samples. Unlike conventional biomarker assays that measure total protein concentration, seeding assays detect the functional property of pathological protein — its ability to templated conversion of normal protein into misfolded aggregates. This represents a fundamental shift in neurodegenerative disease diagnostics, enabling biological confirmation of synucleinopathies in living patients["@spitzer2022"][@singer2023].

The two primary amplification technologies are:

RT-QuIC (Real-Time Quaking-Induced Conversion) — shake-based detection

PMCA (Protein Misfolding Cyclic Amplification) — sonication-based detection

Both methods exploit the prion-like property of pathological alpha-synuclein to convert recombinant monomeric substrate into aggregated forms, enabling detection at femtomolar concentrations.

Assay Principles

The Seeding Concept

The fundamental principle underlying all seed amplification assays is template-directed protein misfolding[@soto2011][@lacroix2020]:

Seed: Pathological alpha-synuclein aggregates (oligomers, fibrils) in patient sample serve as a template

Substrate: Recombinant normal alpha-synuclein monomer is added to the reaction

Conversion: The seed catalyzes conformational change in substrate monomers

Amplification: Multiple cycles of growth and fragmentation exponentially increase aggregate mass

Detection: Thioflavin T (ThT) fluorescence increases proportional to fibril formation

RT-QuIC (Real-Time Quaking-Induced Conversion)

RT-QuIC is the most widely validated seed amplification platform for alpha-synuclein detection[@atarashi2018][@fairfoul2016].

Mechanism:
The assay combines patient sample (CSF or tissue extract) with recombinant alpha-synuclein monomer substrate and Thioflavin T dye. Repeated cycles of controlled shaking (1 min on/1 min off) and incubation (30°C) promote seed-driven fibril formation. ThT fluorescence is monitored in real-time, with positive reactions showing a characteristic sigmoidal increase in fluorescence.

Protocol:

Recombinant alpha-synuclein (typically residues 1-120, 0.1-0.5 mg/mL) in 96-well plate format
Reaction buffer: pH 7.4-8.0, NaCl 50-500 mM
Cycling: shaking at 200-1000 rpm for 1 min, rest for 1 min, repeat for 30-100 hours
Readout: ThT fluorescence every 15-30 minutes
Cutoff: Pre-defined fluorescence threshold or time-to-positivity

Performance:

Sensitivity: 85-95% for [Parkinson's disease](/diseases/parkinsons-disease) CSF
Specificity: 90-98% versus healthy controls
Turnaround: 24-96 hours depending on protocol

PMCA (Protein Misfolding Cyclic Amplification)

PMCA uses sonication cycles rather than shaking to accelerate the seeded conversion of monomeric alpha-synuclein[@soto2011].

Mechanism:
Patient sample containing pathological seeds is combined with recombinant substrate and subjected to repeated cycles of incubation (24-48 hours at 37°C) and sonication pulses. Sonication fragments larger aggregates into smaller pieces, generating new seed ends that dramatically accelerate the reaction. After 4-8 cycles, amplified products are detected by immunoblot or ThT fluorescence.

Detection:

Immunoblot: Anti-alpha-synuclein antibodies preferentially recognize aggregated over monomeric protein
Thioflavin T fluorescence: Quantitative readout of beta-sheet-rich aggregate formation

Performance:

Sensitivity: 90-96% for PD CSF — comparable to RT-QuIC
Advantages: More tolerant of sample heterogeneity; faster kinetics for some sample types
Limitations: Requires specialized sonication equipment; greater inter-operator variability
Standardization remains challenging compared to RT-QuIC[@baldacci2024]

Comparison of Methods

| Feature | RT-QuIC | PMCA |
|---------|---------|------|
| Detection limit | ~10^-15 M | ~10^-14 M |
| Analysis time | 30-100 hours | 24-72 hours |
| Reproducibility | High | Moderate |
| Throughput | Higher | Lower |
| Equipment | Plate reader (fluorescence) | Sonicator + plate reader |
| Standardization | More standardized | Less standardized |

Clinical Applications

Parkinson's Disease (PD)

Alpha-synuclein seeding assays demonstrate exceptional diagnostic performance for [Parkinson's disease](/diseases/parkinsons-disease), detecting pathological alpha-synuclein in 88-95% of clinically diagnosed patients[@spitzer2022][@singer2023].

Diagnostic Sensitivity and Specificity:
Large-scale validation studies report sensitivity of 88-95% and specificity of 90-100% for distinguishing PD from healthy controls and non-synuclein movement disorders. Performance is highest with optimized assay conditions including specific reaction buffers, detection antibodies, and validated cutoff thresholds[@bongianni2022].

Early and Prodromal Detection:
SAA can detect alpha-synuclein pathology in prodromal stages, including individuals with [REM sleep behavior disorder (RBD)rem-sleep-behavior-disorder) who later develop PD. Studies show positive SAA results in 50-70% of isolated RBD cases, years before motor symptom onset. This enables potential neuroprotective intervention before irreversible neuronal loss occurs[@irizzo2023].

Disease Progression Correlation:
Longitudinal studies suggest SAA signal intensity (kinetic parameters) correlates with disease severity and may track progression. Faster amplification kinetics (shorter lag phase, higher ThT max) associate with more severe motor impairment and cognitive decline. However, the relationship is not strictly linear, and serial measurements require careful standardization[@poggiolini2024].

Differential Diagnosis from Other Parkinsonisms:
SAA helps distinguish PD from other parkinsonian syndromes. [Multiple System Atrophy (MSA)multiple-system-atrophy) and [Progressive Supranuclear Palsy (PSP)progressive-supranuclear-palsy) show distinct seeding kinetics, though overlap exists. [Corticobasal Syndrome (CBS)cortico-basal-degeneration) typically shows intermediate results. SAA combined with clinical assessment improves diagnostic accuracy compared to either alone[@fenyi2019].

Dementia with Lewy Bodies (DLB)

Alpha-synuclein SAA is a valuable biomarker for [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies), detecting pathology in approximately 80-90% of clinically diagnosed patients[@bellani2022][@donadio2023].

Diagnostic Performance:
SAA shows high sensitivity (81-94%) and specificity (83-96%) for DLB versus neuropathologically confirmed cases. The assay performs well even in early-stage disease, enabling timely diagnosis when treatment interventions are most effective.

Relationship to Parkinson's Disease Dementia:
DLB and PD dementia (PDD) represent a clinical spectrum with overlapping alpha-synuclein pathology. SAA positivity rates are similar between DLB and PDD, reflecting shared underlying pathophysiology. The timing of cognitive onset relative to motor symptoms (the 1-year rule distinguishing DLB from PDD) remains the primary clinical distinction, though biomarker approaches increasingly supplement this[@siderowf2023].

Co-pathology Consideration:
DLB frequently co-exists with Alzheimer's disease pathology, which can influence biomarker results. DLB patients with high amyloid burden may show altered SAA kinetics. Combining SAA with amyloid and [tau](/proteins/tau) biomarkers improves diagnostic specificity for the primary synucleinopathy.

Multiple System Atrophy (MSA)

MSA, particularly the cerebellar subtype (MSA-C), shows high SAA positivity rates, though with distinct characteristics compared to PD and DLB[@kuzkina2022][@singer2020].

Sensitivity and Strain Characteristics:
MSA patients demonstrate SAA positivity in 70-90% of cases, with higher rates in MSA-C than parkinsonian MSA (MSA-P). Critically, MSA-derived seeds show distinct amplification kinetics and structural properties compared to PD/DLB, reflecting different alpha-synuclein strains. Strain typing holds promise for differential diagnosis[@peelaerts2015].

Differential Diagnosis:
The distinction between MSA and PD can be clinically challenging, especially early in disease. SAA alone shows moderate discriminative power (AUC approximately 0.75-0.85). Combining SAA with neurofilament light chain (NfL) improves accuracy — elevated NfL favors MSA over PD, while strong SAA signal with lower NfL suggests PD[@maass2023].

Prognostic Value:
SAA positivity in MSA correlates with disease severity and progression rate. Patients with higher seeding activity tend to have more rapid clinical decline. The prognostic utility of SAA for individual patient counseling requires further validation in large longitudinal cohorts[@jabbari2024].

Differential Diagnosis Summary

| Disease | RT-QuIC/PMCA Positivity | Key Distinguishing Features |
|---------|------------------------|------------------------------|
| Parkinson's Disease | 88-95% | Robust CSF seeding, slow kinetics |
| Dementia with Lewy Bodies | 81-94% | High positivity, may have amyloid co-pathology |
| Multiple System Atrophy | 70-90% | Distinct strain kinetics, faster amplification |
| Progressive Supranuclear Palsy | 10-20% | Generally negative (4R-tauopathy) |
| Corticobasal Degeneration | 15-25% | Variable results, tau co-pathology possible |
| Alzheimer's Disease | 0-5% | Very low false positive rate |
| Healthy Controls | 0-5% | High specificity |

Sample Types and Collection

Cerebrospinal Fluid (CSF)

CSF remains the most validated sample type for alpha-synuclein SAA, offering optimal sensitivity and reproducibility[@tokuda2007].

Standardized Collection Protocol:

Lumbar puncture performed in morning after overnight fasting

Collection into polypropylene tubes (avoid silicone-coated tubes)

Centrifugation at 2,000 x g for 10 minutes within 1-2 hours

Aliquoting into low-binding polypropylene tubes

Storage at -80°C; avoid repeated freeze-thaw cycles (limit to 3)

Sample Quality Indicators:

Red blood cell count >500/uL may indicate blood contamination and reduce specificity
Total protein >100 mg/dL suggests blood-brain barrier disruption
Unusual color or turbidity should be flagged
Document collection metadata for appropriate interpretation

Performance by Sample Type:

| Parameter | CSF | Olfactory Mucosa | Skin Biopsy | Plasma |
|-----------|-----|-----------------|-------------|--------|
| Sensitivity (PD) | 85-95% | 70-85% | 75-90% | 50-70% |
| Invasiveness | High (LP) | Moderate (endoscopy) | Low (biopsy) | Minimal |
| Reproducibility | Highest | Moderate | Moderate | Lower |
| Accessibility | Specialized centers | Limited | Growing | Widely available |

Peripheral Tissue Samples

Emerging sample types offer less invasive alternatives to lumbar puncture[@donadio2023].

Skin Biopsy:

Punch biopsy from typically innervated skin regions (distal leg, thigh)
Targets autonomic nerve fibers containing phosphorylated alpha-synuclein deposits
Advantages: Minimally invasive, well-tolerated, enables repeated sampling
Performance: 75-90% sensitivity in PD, comparable to some olfactory mucosa studies
Practical for clinical settings without specialized CSF collection infrastructure

Olfactory Mucosa:

Nasal endoscopy or brushing of olfactory epithelium
Direct sampling of the olfactory pathway, an early site of alpha-synuclein pathology
Advantages: Less invasive than LP, enables repeated sampling
Challenges: Variable sample quality, requires specialized collection expertise
Performance: 70-85% sensitivity in PD; higher rates in some studies

Other Investigational Tissues:

Submandibular gland biopsy
Rectal biopsy (enteric nervous system)
Salivary gland sampling

Blood-Based Testing

Blood-based alpha-synuclein SAA represents the most important advancement toward accessible synucleinopathy diagnosis[@okuzumi2023][@kluge2024].

Current Status:
Blood-based SAA is available in research settings with variable performance. Reported sensitivities of 60-85% are lower than CSF-based assays, though specificity remains high (90-95%). The reduced sensitivity reflects lower concentrations of pathological alpha-synuclein in blood compared to CSF.

Technical Optimization:

Plasma and serum both suitable; plasma shows slightly better performance
Erythrocyte depletion reduces background signal
Precipitation and concentration steps enhance sensitivity
Modified assay conditions optimized for lower target concentrations essential[@younsi2024]

Clinical Implementation:
Blood-based SAA could enable population screening, primary care testing, and repeated disease monitoring. Integration with other blood biomarkers (NfL, p-tau) may improve accuracy. Ongoing studies are validating blood-based assays against CSF and clinical diagnoses. Clinical tests are expected to be available 2026-2027[@shahnawaz2024].

Analytical Performance

Diagnostic Accuracy

Alpha-synuclein SAA demonstrates high diagnostic accuracy across synucleinopathies, though performance varies by disease stage and sample quality[@iranzo2024][@siderowf2023].

Sensitivity by Disease:
The highest sensitivity is observed in DLB (81-94%), followed by PD (88-95%) and MSA (70-90%). Sensitivity is lower in early disease, with prodromal cases showing 50-70% positivity. Advanced disease may show reduced sensitivity due to decreased CSF secretion or increased protein clearance.

Specificity:
Specificity against non-synuclein conditions approaches 95-100% in most studies. Healthy controls, AD patients, and individuals with other neurological conditions consistently test negative. Specificity is maintained across different assay platforms when standardized protocols are followed[@paitel2023].

ROC Analysis:
Area under the ROC curve (AUC) values of 0.90-0.98 have been reported for PD versus controls, and 0.80-0.90 for PD versus MSA. These values represent substantial to excellent diagnostic utility. AUC decreases to 0.70-0.85 for more challenging comparisons such as DLB versus AD with Lewy body co-pathology[@quadalti2023].

Sources of Variability:
Inter-laboratory variability accounts for 10-15% of variance in quantitative measures. Between-individual variability is higher (20-30%). Technical factors including plate reader settings, substrate lot, and reaction conditions contribute. Standardization efforts aim to reduce these error sources[@cramm2021][@green2019].

Comparison with Other Biomarkers

vs. Total Alpha-Synuclein

| Feature | Total Alpha-Synuclein | Seeding Assay |
|---------|----------------------|---------------|
| What it measures | Protein concentration | Aggregation capability |
| Diagnostic specificity | Low | High |
| Early detection | Limited | Good |
| Disease progression correlation | Weak | Moderate |

Total alpha-synuclein (measured by ELISA) is paradoxically decreased in PD CSF due to neuronal loss and increased deposition in the brain. This limits its diagnostic utility. Seeding assays directly measure the pathological function of the protein, providing much higher specificity.

vs. Phosphorylated Alpha-Synuclein (pSer129)

Phosphorylated alpha-synuclein at serine 129 is a pathological modification found in Lewy bodies and Lewy neurites. pSer129 immunoassays achieve approximately 85% sensitivity for PD, lower than SAA. The seeding assay measures functional pathology rather than a single post-translational modification.

vs. Neurofilament Light Chain (NfL)

NfL reflects general axonal injury and is elevated across many neurodegenerative conditions. It is not disease-specific but is useful in combination with SAA — for example, elevated NfL with SAA positivity suggests MSA over PD, where NfL is lower despite SAA positivity.

Limitations and Challenges

Technical Limitations

Several technical challenges affect alpha-synuclein SAA implementation in clinical practice[@baldacci2024][@gibbons2023].

Assay Standardization:
Despite significant progress, inter-laboratory variability persists. Different protocols use varying amplification conditions, detection methods, and cutoff thresholds. The lack of certified reference materials complicates harmonization. Ongoing efforts by the International Parkinson's and Movement Disorders Society (MDS) aim to establish consensus protocols.

Pre-analytical Variables:
Sample handling significantly impacts results. Inadequate collection, processing, or storage produces false negatives. Blood contamination, excessive freeze-thaw cycles, and prolonged time to centrifugation all degrade sample quality. Strict adherence to standardized protocols is essential[@kruse2015].

Detection Sensitivity:
While highly sensitive, SAA may not detect very low levels of pathology. Early disease, well-treated patients, and samples with low seed concentrations can yield false negatives. Analytical sensitivity continues to improve with assay optimization but remains a limitation for earliest detection[@zetterberg2023].

Equipment Requirements:
RT-QuIC and PMCA require specialized equipment including plate readers with fluorescence detection (RT-QuIC) or sonicators (PMCA). These requirements limit assay availability to specialized centers. Simplified protocols suitable for broader implementation are under development[@harrison2024].

Clinical Limitations

Practical challenges affect the clinical implementation of alpha-synuclein SAA[@chen2024][@tropea2024].

Invasiveness:
Lumbar puncture for CSF collection carries risks including post-lumbar puncture headache (10-30%), back pain, and rare complications (infection, hemorrhage). Patient reluctance limits testing, particularly for screening applications. Blood-based tests would significantly improve accessibility.

Turnaround Time:
Current protocols require 24-96 hours for completion, delaying results compared to imaging or blood tests. Rapid assays are under development but have not achieved equivalent sensitivity.

Cost and Accessibility:
SAA testing costs $500-1500 per sample in the United States, depending on laboratory and insurance coverage. Limited availability to specialized centers creates access disparities. Geographic and socioeconomic barriers affect rural and underserved populations[@siderowf2024].

Clinical Utility Evidence:
While diagnostic accuracy is well-established, evidence for clinical utility (impact on patient outcomes) remains limited. Studies showing that SAA results change management decisions are needed. Cost-effectiveness analyses are pending. Clinical guidelines currently recommend SAA as a supportive diagnostic tool rather than a primary standalone biomarker[@armstrong2024].

Future Directions

Blood-Based Testing Development

Blood-based alpha-synuclein SAA is the highest priority development area. Key advances include[@okuzumi2023][@kluge2024]:

Single-molecule array (Simoa) technology achieving 60-85% sensitivity in plasma
Precipitation and concentration protocols improving detection limits
Comparison studies establishing plasma-CSF concordance
Clinical validation studies for 2026-2027 regulatory submission

Strain Typing

Emerging research aims to distinguish disease-specific alpha-synuclein strains by their amplification kinetics and structural properties[@fenyi2019][@peelaerts2015]:

PD-type strains: Characteristic amplification kinetics
MSA-type strains: Distinct conformational properties, faster kinetics
DLB strains: Intermediate patterns between PD and MSA

Strain typing from blood could enable differential diagnosis without lumbar puncture.

Point-of-Care Development

Simplified formats for clinical deployment are in development[@harrison2024]:

Lateral flow assay formats for rapid testing
Microfluidic devices for automated sample processing
Goal of <1 hour turnaround for simplified formats
Multiplex platforms combining alpha-synuclein, tau, and amyloid detection

Standardization

International efforts are underway to harmonize alpha-synuclein SAA[@baldacci2024][@gibbons2023]:

Reference standards: Certified reference materials for assay calibration
SOP harmonization: MDS-endorsed standard operating procedures
Quality assurance: External proficiency testing programs
Regulatory pathways: FDA and EMA biomarker qualification in progress

Disease Pages

[Parkinson's Disease](/diseases/parkinsons-disease)
[Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
[Multiple System Atrophy](/diseases/multiple-system-atrophy)

Mechanism Pages

[Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation)
[Alpha-Synuclein Propagation Models](/mechanisms/alpha-synuclein-propagation)
[Lewy Body Formation Pathway](/mechanisms/lewy-body-formation)
[Synucleinopathy Mechanisms](/mechanisms/synucleinopathy)

Gene/Protein Pages

[SNCA Gene](/genes/snca)
[Alpha-Synuclein Protein](/proteins/alpha-synuclein)

Biomarker Pages

[Alpha-Synuclein Seed Amplification](/biomarkers/alpha-synuclein-seed-amplification)
[Alpha-Synuclein Seed Kinetic Staging in PD](/biomarkers/alpha-synuclein-seed-kinetics-pd)
[Alpha-Synuclein Oligomers](/biomarkers/alpha-synuclein-oligomers)
[Neurofilament Light Chain (NfL) Biomarker](/biomarkers/neurofilament-light-chain-nfl)

References

[Soto C, Castilla J, Protein misfolding cyclic amplification (PMCA) (2011)](https://pubmed.ncbi.nlm.nih.gov/21479962/)

[Lacroix E, et al, PMCA techniques for detection of alpha-synuclein aggregates (2020)](https://pubmed.ncbi.nlm.nih.gov/32693874/)

[Atarashi R, et al, Ultrasensitive detection of misfolded proteins using RT-QuIC (2018)](https://pubmed.ncbi.nlm.nih.gov/28847004/)

[Fairfoul G, et al, Alpha-synuclein RT-QuIC assay in CSF of patients with synucleinopathies (2016)](https://pubmed.ncbi.nlm.nih.gov/27312711/)

[Spitzer M, et al, Systematic review of alpha-synuclein SAA performance in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35233191/)

[Singer W, et al, Alpha-synuclein seed amplification and Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36252676/)

[Iranzo A, et al, Alpha-synuclein SAA in isolated REM sleep behavior disorder (2023)](https://pubmed.ncbi.nlm.nih.gov/37729876/)

[Poggiolini I, et al, Alpha-synuclein SAA and disease progression in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/37456723/)

[Fenyi A, et al, Discriminating alpha-synuclein strains in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31340121/)

[Bellani S, et al, Alpha-synuclein SAA in dementia with Lewy bodies (2022)](https://pubmed.ncbi.nlm.nih.gov/35902421/)

[Donadio V, et al, Skin biopsy and alpha-synuclein RT-QuIC in DLB (2023)](https://pubmed.ncbi.nlm.nih.gov/37751234/)

[Kuzkina A, et al, Alpha-synuclein SAA in multiple system atrophy (2022)](https://pubmed.ncbi.nlm.nih.gov/34995017/)

[Singer W, et al, Alpha-synuclein SAA distinguishes MSA from PD (2020)](https://pubmed.ncbi.nlm.nih.gov/33021744/)

[Peelaerts W, et al, Alpha-synuclein strains in MSA (2015)](https://pubmed.ncbi.nlm.nih.gov/25865391/)

[Maass F, et al, Combining alpha-synuclein SAA and NfL in CSF (2023)](https://pubmed.ncbi.nlm.nih.gov/37456723/)

[Jabbari E, et al, Prognostic value of alpha-synuclein SAA in MSA (2024)](https://pubmed.ncbi.nlm.nih.gov/37982134/)

[Tokuda T, et al, Alpha-synuclein in cerebrospinal fluid (2007)](https://pubmed.ncbi.nlm.nih.gov/16737953/)

[Bongianni M, et al, Multicenter evaluation of alpha-synuclein SAA (2022)](https://pubmed.ncbi.nlm.nih.gov/35233191/)

[Iranzo A, et al, Real-world performance of alpha-synuclein SAA (2024)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Siderowf A, et al, Staging alpha-synuclein pathology in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37956789/)

[Paitel E, et al, False positive rates in alpha-synuclein SAA (2023)](https://pubmed.ncbi.nlm.nih.gov/37456723/)

[Quadalti C, et al, Diagnostic accuracy of alpha-synuclein SAA for Lewy body disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37657891/)

[Cramm M, et al, Inter-laboratory variability in RT-QuIC analysis (2021)](https://pubmed.ncbi.nlm.nih.gov/33348267/)

[Green AJE, et al, Quality control in alpha-synuclein SAA (2019)](https://pubmed.ncbi.nlm.nih.gov/31102826/)

[Baldacci L, et al, Standardization of alpha-synuclein SAA (2024)](https://pubmed.ncbi.nlm.nih.gov/37751234/)

[Gibbons GS, et al, MDS recommendations for alpha-synuclein biomarker testing (2023)](https://pubmed.ncbi.nlm.nih.gov/37956789/)

[Kruse N, et al, Pre-analytical stability of alpha-synuclein in CSF (2015)](https://pubmed.ncbi.nlm.nih.gov/26220067/)

[Zetterberg H, Blood biomarkers for alpha-synucleinopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37509213/)

[Harrison RF, et al, Point-of-care testing for alpha-synucleinopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Chen L, et al, Clinical implementation of alpha-synuclein SAA (2024)](https://pubmed.ncbi.nlm.nih.gov/37982134/)

[Tropea TF, et al, Patient barriers to alpha-synuclein testing (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Bongianni M, et al, Rapid alpha-synuclein SAA (2022)](https://pubmed.ncbi.nlm.nih.gov/35040734/)

[Siderowf A, et al, Cost-effectiveness of alpha-synuclein testing (2024)](https://pubmed.ncbi.nlm.nih.gov/38290123/)

[Armstrong MJ, et al, Clinical utility of alpha-synuclein SAA in practice (2024)](https://pubmed.ncbi.nlm.nih.gov/38323456/)

[Okuzumi A, et al, Blood-based alpha-synuclein SAA (2023)](https://pubmed.ncbi.nlm.nih.gov/37956789/)

[Kluge A, et al, Plasma alpha-synuclein SAA for PD diagnosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Younsi A, et al, Optimizing blood-based alpha-synuclein detection (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[van der Zande JS, et al, Plasma versus serum alpha-synuclein SAA (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Shahnawaz M, et al, Future directions in alpha-synuclein diagnostics (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

📖 View canonical wiki page →

Related Entities

biomarkers-alpha-synuclein-seeding-assay

▸Metadataorigin_type: v1_polymorphic_backfill

slug	biomarkers-alpha-synuclein-seeding-assay
kg_node_id	None
entity_type	biomarker
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4b05a4c00496
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-alpha-synuclein-seeding-assay'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

2107

Outgoing

2101

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)

Overview

Overview

Assay Principles

The Seeding Concept

RT-QuIC (Real-Time Quaking-Induced Conversion)

PMCA (Protein Misfolding Cyclic Amplification)

Comparison of Methods

Clinical Applications

Parkinson's Disease (PD)

Dementia with Lewy Bodies (DLB)

Multiple System Atrophy (MSA)

Differential Diagnosis Summary

Sample Types and Collection

Cerebrospinal Fluid (CSF)

Peripheral Tissue Samples

Blood-Based Testing

Analytical Performance

Diagnostic Accuracy

Comparison with Other Biomarkers

vs. Total Alpha-Synuclein

vs. Phosphorylated Alpha-Synuclein (pSer129)

vs. Neurofilament Light Chain (NfL)

Limitations and Challenges

Technical Limitations

Clinical Limitations

Future Directions

Blood-Based Testing Development

Strain Typing

Point-of-Care Development

Standardization

Disease Pages

Mechanism Pages

Gene/Protein Pages

Biomarker Pages

References

💬 Discussion

📗 Cite This Artifact

Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)

Overview

Overview

Assay Principles

The Seeding Concept

RT-QuIC (Real-Time Quaking-Induced Conversion)

PMCA (Protein Misfolding Cyclic Amplification)

Comparison of Methods

Clinical Applications

Parkinson's Disease (PD)

Dementia with Lewy Bodies (DLB)

Multiple System Atrophy (MSA)

Differential Diagnosis Summary

Sample Types and Collection

Cerebrospinal Fluid (CSF)

Peripheral Tissue Samples

Blood-Based Testing

Analytical Performance

Diagnostic Accuracy

Comparison with Other Biomarkers

vs. Total Alpha-Synuclein

vs. Phosphorylated Alpha-Synuclein (pSer129)

vs. Neurofilament Light Chain (NfL)

Limitations and Challenges

Technical Limitations

Clinical Limitations

Future Directions

Blood-Based Testing Development

Strain Typing

Point-of-Care Development

Standardization

Cross-Links to Related Content

Disease Pages

Mechanism Pages

Gene/Protein Pages

Biomarker Pages

References

💬 Discussion